BIO2024 – Two sessions related to M&A in biotech, each offering unique perspectives while sharing common themes “From Incubation to Acquisition – The Growth Journey of an Early-Stage Company” centered around Serotiny, a therapeutic discovery company that designs new genes…
The looming specter of the 2024 U.S. elections casts a long shadow over its tech landscape, with few entrepreneurs fully aware of the potential fallout of proposed tax reforms under a possible second Biden term Serge JonnaertCEO & M&A Advisor…
Delivering better quality results, faster, more efficiently, and at a lower cost by Serge Jonnaert – Managing Director It’s May 2024, and the conversation around AI, particularly in M&A has never been more pertinent. Some people recoil at the thought,…
This is a call-out to all #techCEOs! Prepare yourself for a fun, rich, healthy, and joyful 2024. No more worries about making payroll, funding rounds, boring board calls, email overload, markets, competitors, and forecasts. Start to measure life in beach,…
Landing ‘a big one’ is still the aspiration of most software CEOs, and rightfully so. The technology sector has the third-most billionaires (332) in the world, behind finance and investments, representing a total of $2.1 trillion in wealth. A well-executed…